Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023 By Sarah EllinwoodJune 2, 2023 Funding, Awards and Collaborations BCWorld Healthcare and ReGelTec Enter Exclusive Distribution Agreement for [….]
Delfi Diagnostics, a Baltimore-based company developing liquid biopsy tests for early cancer detection, will highlight its next-generation liquid biopsy platform at the American Association for Cancer Research’s (AACR) 2023 annual meeting in April.
Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe’s multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR.
Illumina has deep pockets, Guardant Health has deep experience. But this company with a growing team in Palo Alto says it will be able to offer early-cancer detection for less.
This round of financing was led by DFJ Growth with participation from Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, and all existing investors including Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, and Windham Venture Partners.
Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer
NEWS PROVIDED BY
Delfi Diagnostics
Jul 12, 2022, 08:00 ET
SHARE THIS ARTICLE
BALTIMORE, July 12, 2022 /PRNewswire/ — Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Jessica Meng as the company’s first Chief Commercial Officer.
Jessica Meng
“Jessica is a strategic leader who has scaled commercial organizations in therapeutics and diagnostics and knows what it takes to commercialize successful oncology products,” said Delfi Founder and CEO Victor Velculescu, MD, PhD. “We are excited to have her leadership as we prepare to introduce the first products on the Delfi platform.”
Jessica is a proven commercial leader with a 20+ year track record in healthcare and extensive product launch leadership. She most recently led the Women’s Health Division of Myovant Sciences as General Manager and Vice President of Sales & Marketing, where she played a key role in the formation of the co-promotion partnership with Pfizer. Prior to Myovant, Jessica was Vice President of Marketing for Veracyte, launching multiple genomic diagnostic products in oncology and pulmonology and helping to grow the commercial organization’s headcount from 50…
ASCO 2022 press releases from the BioHealth Capital Region and Greater Philadelphia
Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center’s Biomarker Development Program, led by Howard I. Scher, MD, FASCO. The agreement creates a framework for Delfi and MSK researchers to work together on a range of projects studying Delfi’s liquid biopsy platform, advancing their shared mission of developing high performing cancer testing.
The cancer diagnostics market is surging, with an overall revenue growth expectation of hundreds of billions of dollars within the next eight years. The market is expected to grow to $257 billion by 2030, more than double the $124.9 billion valuation in 2021.
The Baltimore biotech ecosystem is thriving. And new, big and bold life sciences development projects are in the works, leading many to project Charm City as the next sector of the BioHealth Capital Region (BHCR) to boom.
